Аннотация
Хорошо известно, что у пациентов с диабетом 1 и 2-го типа повышены риски клинических осложнений микро- и макрососудистых заболеваний. При этом связь между повышенным уровнем глюкозы и микрососудистыми осложнениями, по-видимому, напрямую коррелирует и в целом специфична для диабета. Однако связь с макрососудистым риском является более сложной, многофакторной и не ограничивается только гипергликемией. В статье рассматривается взаимосвязь микро- и макрососудистого повреждения органов-мишеней при сахарном диабете и сердечно-сосудистого риска. Приводится обзор исследований эффективности снижения уровня глюкозы при диабете 2-го типа в свете сердечно-сосудистой безопасности. Обсуждаются современные методы терапии сахарного диабета. Особое внимание уделено самоконтролю гликемии как одному из важнейших факторов в управлении сахарным диабетом и профилактики осложнений.
Ключевые слова: сахарный диабет, сердечно-сосудистый риск, контроль гликемии, самоконтроль.
Ключевые слова: сахарный диабет, сердечно-сосудистый риск, контроль гликемии, самоконтроль.
Об авторе
К.В. Овсянников1,2, Е.А. Праскурничий1
1 Медико-биологический университет инноваций и непрерывного образования ФГБУ «ГНЦ ФМБЦ им. А.И. Бурназяна» ФМБА России, Москва, Россия;
2 ФГБУЗ «Клиническая больница №85» ФМБА, Москва, Россия
kvovsn@gmail.com
Список литературы
1. Davies MJ, DÁlessio DA, Fradkin J et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes EASD. Diabetologia. 2018; 61: 2461–98.
2. Sattar N, Rawshani A, Franzen S et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019; 139: 2228–37.
3. Zucker I, Schohat T, Dankner R, Chodick G. New onset diabetes in adulthood is associated with a substantial risk for mortality at all ages: a population based historical cohort study with a decade-long follow-up. Cardiovasc Diabetol. 2017; 16: 105. DOI: 10.1186/s12933-017-0583-x
4. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018; 17: 83. DOI: 10.1186/s12933-018-0728-6
5. Lind M, Svensson A-M, Kosiborod M et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014; 371: 1972–82.
6. Rawshani A, Rawshani A, Sattar N et al. Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2019; 139: 1900–12.
7. Brownrigg JRW, Hughes CO, Burleigh D et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level-cohort study. Lancet Diabetes Endocrinol. 2016; 4: 588–97.
8. Climie RE, Gallo A, Picone DS et al. Measuring the interaction between the macro- and micro-vasculature. Front Cardiovasc Med. 2019. DOI: 10.3389/fcvm.2019.00169
9. Ziegler T, Rahmnann FA, Jurisch V, Kupatt C. Atheroclerosis and the capillary network; pathophysiology and potential therapeutic strategies. Cell. 2020; 9 (1): 50. DOI: 10.3390/cells9010050
10. Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2012; 32: 2052–9.
11. Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019; 129: 3990–4000.
12. U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–53.
13. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000; 321: 405–12.
14. Gerstein HC, Miller ME, Byington RP et al. for The Action to Control cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545–59.
15. Heller SR on behalf of the ADVANCE collaborative group. A summary of the ADVANCE trial. Diabetes Care. 2009; 32 (Suppl. 2): S357–S361.
16. Duckworth W, Abraira C, Moritz T et al. for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129–39.
17. The ORIGIN Trial Investigators. Basla insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319–28.
18. Marso SP, McGuirre DK, Zinman B et al Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017; 377: 723–32.
19. Holman RR, Coleman RL, Chan JCN et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose intolerance (ACE): a randomized, double blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 877–86.
20. Vaccaro O, Masulli M, Nicolucci A et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017; 5: 887–97.
21. Rosenstock J, Kahn SE, Johansen OE et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA randomized clinical trial. JAMA. 2019; 322: 1155–66.
22. Kernan WN, Viscoli CM, Furie KL et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016; 374: 1321–31.
23. Zannad F, Cannon CP, Cushman WC et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385: 2067–76.
24. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 32: 69–79.
25. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317–26.
26. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232–42.
27. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med. 2016; 375: 311–22.
28. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med. 2016; 375: 1834–44.
29. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlles trial. Lancet. 2018; 392: 1519–29.
30. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121–30.
31. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381: 841–51.
32. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247–57.
33. Holman RR, Bethel MA, Mentz RJ et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377: 1228–39.
34. Lim S, Kim KM, Nauck MA. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab. 2018; 29: 238–48.
35. Marx N, Libby P Cardiovascular benefits of GLP-1 receptor agonism. JACC Basic Transl Sci. 2018; 3: 858–60.
36. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–28.
37. Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375: 323–34.
38 Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644–57.
39. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295–306.
40. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–57.
41. Furtao RHM, Bonaca MP, Raz I et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Subanalysis from DECLARE-TIMI 58 trial. Circulation. 2019; 139: 2516–27.
42. Kato ET, Silverman MG, Mosenzon O et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019; 139: 2528–36.
43. Cannon CP, Pratley R, Dagogo-Jack S et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020; 383: 1425–35.
44. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced rejection fraction. N Engl J Med. 2019; 381 (21): 1995–2008.
45. Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. 383: 1413–24.
46. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295–306.
47. Heerspink HJL, Stefansson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–46.
48. Marx N. Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. Eur Heart J. 2020; 41: 3359–62.
49. Sattar N, McGuire DK. Prevention of CVoutcomes in antihyperglycemic drug-naive patients with type 2 diabetes with, or at elevated risk of,
ASCVD: to start or not to start with metformin. Eur Heart J. 2021; 42: 2574–76.
50. Fang M. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. N Engl J Med. 2021; 384 (23): 2219–28. URL: https: //pubmed.ncbi.nlm.nih.gov/34107181/
51. Gregg EW, Hora I, Benoit SR. Resurgence in Diabetes-Related Complications JAMA. 2019; 321 (19): 1867–8. DOI: 10.1001/jama.2019.3471
52. Heinemann L. EASD diabetes technology meeting: medical associations are on track. J Diabetes Sci Technol. 2014 Jul;8(4):900-3. doi: 10.1177/1932296814534630. Epub 2014 May 18. PMID: 24876444; PMCID: PMC4764238.
53. Bailey TS, Wallace JF, Pardo S, Warchal-Windham ME, Harrison B, Morin R, Christiansen M. Accuracy and User Performance Evaluation of a New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device. J Diabetes Sci Technol. 2017 Jul;11(4):736-743. doi: 10.1177/1932296816680829. Epub 2017 Feb 1. PMID: 28617617; PMCID: PMC5588817.
54. Harrison B, Brown D. Accuracy of a blood glucose monitoring system that recognizes insufficient sample blood volume and allows application of more blood to the same test strip. Expert Rev Med Devices. 2020 Jan;17(1):75-82. doi: 10.1080/17434440.2020.1704253. Epub 2020 Jan 10. PMID: 31825686.
Для цитирования:Овсянников К.В., Праскурничий Е.А. Роль контроля гликемии у больных сахарным диабетом 2-го типа. Клинический разбор в общей медицине. 2023; 4 (8): 74–82. DOI: 10.47407/kr2023.4.8.00334
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)